quantitative
Analysis v1
Strong Support
For people with serious heart disease who are already taking cholesterol-lowering pills, adding one of two special drugs (evolocumab or alirocumab) can lower their chances of having a major heart problem—like a heart attack—by about 15% over a few years.
1
0
Evidence from Studies
Supporting (1)
1
Community contributions welcome
1
PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
Narrative Review
In Vitro
2020The study looked at the same drugs in the same kind of patients and found they reduced heart problems by about 15%, just like the claim says.
Contradicting (0)
0
Community contributions welcome
No contradicting evidence found
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.